End-on versus parallel radiofrequency lesioning for neurotomy of the cervical medial branch nerves: a study protocol of a prospective, randomized, double-blind clinical trial: the "EndPaRL" study.

BACKGROUND: Cervical facet joint disease is a common source of neck pain and its prevalence increases with aging. Conservative multimodal management options (e.g., strengthening of neck muscles, non-steroidal anti-inflammatory medications, massage, and thermal modalities) often fail to relieve pain. Cervical medial branch nerve (CMBN) radiofrequency neurotomy (RFN) is an effective minimally invasive technique for treating chronic neck pain secondary to facet joint disease. An end-on approach for this procedure has been proposed that may be technically easier and require less time while reducing post-procedural discomfort. The protocol presented here is for a study that aims to compare the efficacy of a new end-on approach using multi-tined cannulae, against the conventional parallel technique that employs straight cannulae for RFN of the CMBN in patients with chronic neck pain due to cervical facet joint disease. METHODS: A multicentre randomized, non-inferior, active comparator-controlled trial will be conducted with two parallel groups and blinding of participants and outcome assessor. The study will include 72 adults with chronic neck pain secondary to facet joint disease who are candidates for RFA of the CMBN. Participants will be randomized to either the conventional parallel or the end-on approach in a 1:1 ratio. The intensity of pain and pain-related domains (function, quality of life, sleep, adverse effects of the interventions, analgesic intake) will be measured at 1, 3, 6, and 12 months after the procedure. DISCUSSION: Neck pain secondary to cervical facet joint disease is prevalent and RFA of the CMBN is a validated treatment for relieving it. The conventional parallel technique can be technically challenging, and it can be associated with adverse effects while the newer end-on approach has the potential of being a simpler technique with less adverse effects. This trial will be the first non-inferiority study to compare the clinical efficacy of the end-on approach against the conventional parallel approach for RFN of CMBN in patients with chronic neck pain due to cervical facet joint disease. TRIAL REGISTRATION: ClinicalTrials.gov NCT05818774. Registered on April 20, 2023.

A systematic review of the efficacy of ketamine for craniofacial pain.

Background: Craniofacial pain (CFP) poses a burden on patients and health care systems. It is hypothesized that ketamine, an N-methyl-d-aspartate (NMDA) receptor antagonist, can reverse central sensitization associated with causation and propagation of CFP. This systematic review aims to assess the role of ketamine for CFP. Methods: Databases were searched for studies published up to September 26, 2022, investigating the efficacy of ketamine for adults with CFP. Primary outcome was the change in pain intensity at 60 min postintervention. Two reviewers screened and extracted data. Registration with PROSPERO was performed (CRD42020178649). Results: Twenty papers (six randomized controlled trials [RCTs], 14 observational studies) including 670 patients were identified. Substantial heterogeneity in terms of study design, population, dose, route of administration, treatment duration, and follow-up was noted. Bolus dose ranged from 0.2-0.3 mg/kg (intravenous) to 0.4 mg/kg (intramuscular) to 0.25-0.75 mg/kg (intranasal). Ketamine infusions (0.1-1 mg/kg/h) were given over various durations. Follow-up was short in RCTs (from 60 min to 72 h) but longer in observational studies (up to 18 months). Ketamine by bolus treatment failed to reduce migraine intensity but had an effect by reducing intensity of aura, cluster headache (CH), and trigeminal neuralgia. Prolonged ketamine infusions showed sustainable reduction of migraine intensity and frequency of CH attacks, but the quality of the evidence is low. Conclusion: Current evidence remains conflicting on the efficacy of ketamine for CFP owing to low quality and heterogeneity across studies. Ketamine infusions are suggested to provide sustained improvement, possibly because of prolonged duration and higher dosage of administration. RCTs should focus on the dose-response relationship of prolonged ketamine infusions on CFP.

Contexte: La douleur crânio-faciale représente un fardeau pour les patients et les systèmes de soins de santé. L'hypothèse a été émise que la kétamine, un antagoniste du récepteur N-méthyl-D-aspartate (NMDA), peut inverser la sensibilisation centrale associée à la causalité et à la propagation de la douleur crânio-faciale. Cette revue systématique vise à évaluer le rôle de la kétamine dans la douleur crânio-faciale.Méthodes: Les bases de données ont été consultées pour y repérer les études publiées jusqu'au 26 septembre 2022 qui portaient sur l'efficacité de la kétamine chez les adultes atteints de douleur crânio-faciale. Le critère de jugement principal était le changement de l'intensité de la douleur 60 minutes après l'intervention. Deux évaluateurs ont examiné et extrait les données. L'inscription auprès de PROSPERO a été réalisée (CRD42020178649).Résultats: Vingt articles (six essais contrôlés randomisés, 14 études observationnelles) incluant 670 patients ont été répertoriées. Une hétérogénéité considérable en matière de devis d'étude, de population, de dose, de voie d'administration, de durée du traitement et de suivi a été notée. La dose bolus variait de 0,2 à 0,3 mg/kg (voie intraveineuse) à 0,4 mg/kg (voie intramusculaire) et à 0,25-0,75 mg/kg (voie intranasale). Les perfusions de kétamine (0,1-1 mg/kg/h) étaient administrées sur différentes durées. Le suivi était court dans les études contrôllées randomisées (de 60 min à 72 h) mais plus long dans les études observationnelles (jusqu'à 18 mois). La kétamine par traitement bolus n'a pas réussi à réduire l'intensité de la migraine mais a eu un effet en réduisant l'intensité de l'aura, la céphalée en grappe et la névralgie du trijumeau. Les perfusions de kétamine prolongées ont montré une réduction durable de l'intensité de la migraine et la fréquence des crises de CH, mais la qualité des données probantes est faible.Conclusions: Les données probantes actuelles demeurent contradictoires sur l'efficacité de la kétamine pour la douleur crânio-faciale en raison de la faible qualité et de l'hétérogénéité des études. Il est suggéré que les perfusions de kétamine procurent une amélioration soutenue, peut-être en raison de leur durée prolongée et de leur posologie d'administration plus élevée. Les essais contrôlés randomisés devraient se concentrer sur la relation dose-réponse des perfusions prolongées de kétamine sur la douleur crâno-faciale.

A Scoping Review of Epidural Spinal Cord Stimulation for Improving Motor and Voiding Function Following Spinal Cord Injury.

Objectives: To identify and synthesize the existing evidence on the effectiveness and safety of epidural spinal cord stimulation (SCS) for improving motor and voiding function and reducing spasticity following spinal cord injury (SCI). Methods: This scoping review was performed according to the framework of Arksey and O'Malley. Comprehensive serial searches in multiple databases (MEDLINE, Embase, Cochrane Central, Cochrane Database of Systematic Reviews, LILACS, PubMed, Web of Science, and Scopus) were performed to identify relevant publications that focused on epidural SCS for improving motor function, including spasticity, and voiding deficits in individuals with SCI. Results: Data from 13 case series including 88 individuals with complete or incomplete SCI (American Spinal Injury Association Impairment Scale [AIS] grade A to D) were included. In 12 studies of individuals with SCI, the majority (83 out of 88) demonstrated a variable degree of improvement in volitional motor function with epidural SCS. Two studies, incorporating 27 participants, demonstrated a significant reduction in spasticity with SCS. Two small studies consisting of five and two participants, respectively, demonstrated improved supraspinal control of volitional micturition with SCS. Conclusion: Epidural SCS can enhance central pattern generator activity and lower motor neuron excitability in individuals with SCI. The observed effects of epidural SCS following SCI suggest that the preservation of supraspinal transmission is sufficient for the recovery of volitional motor and voiding function, even in patients with complete SCI. Further research is warranted to evaluate and optimize the parameters for epidural SCS and their impact on individuals with differing degrees of severity of SCI.

Factors associated with success and failure of patient-controlled oral analgesia after total hip and knee arthroplasty: a historical comparative cohort study.

PURPOSE: Patient-controlled oral analgesia (PCOA) is a novel method of oral opioid administration using set doses of short-acting oral opioids self-administered by patients with a "lockout" period as part of a multimodal regimen. Failure of PCOA can result in severe postoperative pain necessitating use of intravenous patient-controlled analgesia (IV-PCA) with its potential complications. This study evaluated factors related to success or failure of PCOA following total hip arthroplasty (THA) and total knee arthroplasty (TKA). METHODS: We conducted a retrospective cohort study of all adults who underwent THA and TKA at our institution by extracting data from the proprietary database of our acute pain service. Patient, anesthetic, and surgical variables associated with PCOA failure defined as inadequate analgesia requiring conversion to IV-PCA within 24 hr following THA and TKA were evaluated. Univariable and multivariable logistic regression analyses were performed to identify predictors of PCOA failure. RESULTS: Of the 926 patients who underwent THA or TKA (n = 411 and 515, respectively), 147 (15.9%) patients (67 THA and 80 TKA patients) had PCOA failure with moderate-to-severe pain. Multivariable regression analysis showed that PCOA failure occurred in those with younger age (adjusted odds ratio [aOR] per year of age, 0.97; 99% CI, 0.95 to 0.99; P < 0.001), preoperative chronic use of controlled-release opioids (aOR, 3.45; 99% CI, 1.60 to 7.35; P < 0.001), and with the use of general anesthesia vs spinal anesthesia (aOR, 2.86; 99% CI, 1.20 to 6.84; P = 0.002). CONCLUSION: The use of PCOA provides adequate analgesia to a majority of patients undergoing THA and TKA. Factors predictive for PCOA failure should be considered when choosing the primary breakthrough analgesic modality following THA/TKA.

RéSUMé: OBJECTIF: L'analgésie orale contrôlée par le patient (AOCP) est une méthode novatrice d'administration d'opioïdes oraux qui utilise des doses pré-établies d'opioïdes oraux à courte action auto-administrées par les patients avec un intervalle minimal entre les doses dans le cadre d'un régime multimodal. Le non-fonctionnement d'une AOCP peut entraîner une douleur postopératoire grave nécessitant le recours à une analgésie intraveineuse contrôlée par le patient (ACP-IV), ce qui s'accompagne de complications potentielles. Cette étude a évalué les facteurs liés à la réussite ou à l'échec de l'AOCP à la suite d'une arthroplastie totale de la hanche (ATH) ou du genou (ATG). MéTHODE: Nous avons réalisé une étude de cohorte rétrospective de tous les adultes ayant subi une ATH ou une ATG dans notre établissement en extrayant les données de la base de données de notre service de douleur aiguë. Les variables liées au patient, à l'anesthésie, et à la chirurgie et associées à un échec de l'AOCP, défini comme une analgésie inadéquate exigeant la conversion en ACP-IV dans les 24 heures suivant l'ATH ou l'ATG, ont été évaluées. Des analyses de régression logistique univariée et multivariée ont été effectuées pour identifier les prédicteurs d'un échec de l'AOCP. RéSULTATS: Sur les 926 patients ayant subi une ATH ou une ATG (n = 411 et 515, respectivement), l'AOCP n'a pas fonctionné chez 147 (15,9 %) patients (67 patients d'ATH et 80 d'ATG), entraînant une douleur modérée à grave. L'analyse de régression multivariée a montré que les échecs de l'AOCP sont survenus chez les personnes plus jeunes (rapport de cotes ajusté [RCA] par année d'âge, 0,97; IC 99 %, 0,95 à 0,99; P < 0,001), lors d'une utilisation préopératoire chronique d'opioïdes à libération contrôlée (RCA, 3,45; IC 99 %, 1,60 à 7,35; P < 0,001), et lors d'une anesthésie générale vs une rachianesthésie (RCA, 2,86; IC 99 %, 1,20 à 6,84; P = 0,002). CONCLUSION: L'utilisation de l'AOCP procure une analgésie adéquate à la majorité des patients subissant une ATH ou une ATG. Les facteurs prédictifs d'un échec de l'AOCP devraient être pris en considération lors du choix de la principale modalité analgésique après une ATH/ATG.

Finding Optimal Neuromodulation for Chronic Pain: Waves, Bursts, and Beyond.

BACKGROUND: Spinal cord stimulation (SCS) has emerged as state-of-the-art evidence-based treatment for chronic intractable pain related to spinal and peripheral nerve disorders. Traditionally delivered as steady-state, paraesthesia-producing electrical stimulation, newer technology has augmented the SCS option and outcome in the last decade. OBJECTIVE: To present an overview of the traditional and newer SCS waveforms. MATERIALS AND METHODS: We present a short literature review of SCS waveforms in reference to newer waveforms and describing paraesthesia-free, high frequency, and burst stimulation methods as well as advances in waveform paradigms and programming modalities. Pertinent literature was reviewed, especially in the context of evolution in the waveforms of SCS and stimulation parameters. RESULTS: Conventional tonic SCS remains one of the most utilized and clinically validated SCS waveforms. Newer waveforms such as burst stimulation, high-frequency stimulation, and the sub-perception SCS have emerged in the last decades with favorable results with no or minimal paraesthesia, including in cases otherwise intractable to conventional tonic SCS. The recent evolution and experience of closed-loop SCS is promising and appealing. The experience and validation of the newer SCS waveforms, however, remain limited but optimistic. CONCLUSIONS: Advances in SCS device technology and waveforms have improved patient outcomes, leading to its increased utilization of SCS for chronic pain. These improvements and the development of closed-loop SCS have been increasingly promising development and foster a clinical translation of improved pain relief as the years of research and clinical study beyond conventional SCS waveform come to fruition.

Thoracolumbar Interfascial Plane Block for Spinal Cord Stimulator System Implantation: A Case Series.

Thoracolumbar interfascial plane block (TLIPB) has recently been described for postoperative analgesia after thoracolumbar spine surgery. This block is minimally invasive, relatively safe, and easy to perform. TLIPB can potentially decrease opioid requirements and enhance recovery following spine surgery. We describe the sonoanatomic landmarks of this technique, and we report results of this retrospective case series on analgesic impact of this block in patients undergoing implantation of spinal cord stimulation systems. Clinical studies are required to investigate the analgesic role of TLIPB for spinal thoracolumbar surgery.

Quality of chronic pain interventional treatment guidelines from pain societies: Assessment with the AGREE II instrument.

BACKGROUND AND OBJECTIVE: Procedures to relieve pain are performed frequently but there are concerns about patient selection, appropriate image guidance, frequency and training for physicians. Patients, healthcare providers, policymakers and licensing bodies seek evidence-based recommendations to use these interventions judiciously. In this review we appraised the methodological quality of recent clinical practice guidelines (CPGs) for interventional pain procedures. DATABASE AND DATA TREATMENT: A systematic search of the medical literature was performed. Three trained appraisers independently evaluated the methodological quality of the CPGs using a validated instrument, the Appraisal of Guidelines in Research and Evaluation II (AGREE II). Six domains were considered: 1) score and purpose; 2) stakeholder involvement; 3) rigour of development; 4) clarity of presentation; 5) applicability and 6) editorial independence. A total of 23 items were scored. CPGs were deemed 'high quality' if a mean scaled score above 60% for rigour of development and for two other domains was obtained. RESULTS: Mean scaled domain quality scores ranged from 61.72% to 69.99%. Despite being based on modest levels of evidence, two of the four included CPGs were considered to be of high methodological quality. The AGREE II scores across the four guidelines exhibited good inter-rater reliability. None of the guidelines involved key stakeholders such as patients, other healthcare providers, and payers. CONCLUSIONS: All four CPGs were limited by a weak execution of the guideline development process. There is a need to develop methodologically sound evidence-based guidelines for the use of interventional pain procedures using a rigorous process that involves all relevant stakeholders. SIGNIFICANCE: This systematic review appraises the methodological quality of existing CPGs on interventional procedures using a validated epidemiological tool (AGREE II). The aims of this review were to identify methodological and knowledge gaps in existing CPGs. Findings of this study will help in development of a high-quality CPG that can assist healthcare providers and patients in making informed decisions while ensuring that the right intervention is performed for the right patient at the right time. The quality of the evidence provided by the CPGs provided in support of their recommendations was also evaluated.

Interventions for myofascial pain syndrome in cancer pain: recent advances: why, when, where and how.

PURPOSE OF REVIEW: Pain is one of the most feared and most common symptoms of cancer, experienced by 38-85% of patients. Pain in terminally ill cancer patients is a multidimensional experience caused by a diverse array of factors - cancer itself, its treatment or other causes. Studies have shown a high incidence of myofascial pain syndrome (MPS) in patients with cancer and the knowledge of myofascial trigger points (MTrPs) is important to address and manage existing pain, and to prevent the recurrence of pain. This review aims to summarize recent advances in interventions for managing MPS in patients with cancer. RECENT FINDINGS: Database searches were conducted on MEDLINE, CINAHL, and Google Scholar to locate all studies published from inception until April 2019 using the keywords cancer pain, myofascial pain, TrPs with emphasis of any methodological quality that included interventions for MPS. MPS in advanced cancer patients are more commonly observed along with other cancer pains rather than independently with a prevalence of 11.9-48% in those patients diagnosed with cancer of head and neck and breast cancer. SUMMARY: Interventional therapies employing ultrasound guided injection of the MTrPs is gaining popularity in the management of MPS in cancer pain and may be a better alternative than the use of opioid analgesics in the multidisciplinary management.

Correction to: A Review of Current Denervation Techniques for Chronic Hip Pain: Anatomical and Technical Considerations.

In the original publication, the legend in the Figure 1 caption were missing and Table 2 was not presented correctly.

A Review of Current Denervation Techniques for Chronic Hip Pain: Anatomical and Technical Considerations.

PURPOSE OF REVIEW: Percutaneous radiofrequency (RF) denervation of articular sensory nerves of the hip joint is a minimally invasive neurotomy technique that can provide pain relief in patients with chronic hip pain. There has been an increase in the number of publications on RF denervation of the hip over the last few years although many questions remain regarding anatomical targets, technical aspects, selection criteria, and evidence for effectiveness. RECENT FINDINGS: For this updated review, publications were identified by searching MEDLINE and other medical literature databases from inception through November 30, 2018. Existing knowledge of hip joint innervation was reviewed and data on patient selection, prognostication of analgesic benefit from ablation by using local anesthetic blocks, current techniques of performing hip joint ablation, analgesic success, functional outcomes, and adverse effects were critically reviewed and analyzed. Sensory denervation of the anterior hip joint using RF current is a viable treatment option for management of chronic hip pain after conservative methods fails to do so. We have synthesized knowledge from papers on techniques of ablation and from recently elaborated anatomical details. We also provide suggestions regarding anticipated outcomes of the procedure. Our review of existing literature indicates evidence for analgesic benefits, improvement in function, and a low incidence of adverse effects of RF ablation of sensory innervation to the hip joint. Future research should focus on refining the technique of ablation and monitoring of long-term outcomes.

Demographic Variables and Its Effect on Emotional Intelligence: A Study on Indian Service Sector Employees.

In past few decades, emotional intelligence (EI) has gained much popularity worldwide. Intelligence quotient alone is not enough in today's age for achieving success and hence for developing a person's ability, the fields of psychology and neurosciences have highlighted the importance of EI, which is a person's response toward feelings and emotions. In this study, relationship of various demographic variables with EI, as measured by Trait Emotional Intelligence Questionnaire-Short Form, has been highlighted. The study has been conducted on a sample of 424 employees belonging to the Indian service sector. The results showed that demographic variables have an impact over EI. Organizations can take a cue from the study and adhere to diversity management practices to ensure financial gains and growth.